Experts Weigh Benefits and Risks of Psychedelics in Health
A recent session at the American Public Health Association highlighted the therapeutic potential and challenges of psychedelics.
11 million Americans microdosed psilocybin in 2025, showing growing interest.
FDA is set to decide on psilocybin for treatment-resistant depression by 2027.
Concerns exist over the exclusion of complex mental health cases in clinical trials.
During a recent session at the American Public Health Association, experts discussed the therapeutic benefits and risks associated with psychedelic substances. The session, titled "Psychedelics and Public Health," highlighted the increasing interest in psychedelics as potential treatments for various mental health conditions, particularly among veterans and individuals suffering from treatment-resistant disorders.
Research indicates that psychedelics, particularly psilocybin, have shown promise in alleviating symptoms of anxiety, PTSD, and depression. In 2025, approximately 11 million Americans reportedly engaged in microdosing psilocybin, which advocates claim can enhance mental well-being. However, negative experiences, often referred to as "bad trips," can occur, though they may be reduced in supportive environments.
The U.S. Food and Drug Administration (FDA) has recently finalized guidelines for studying psychedelics and is expected to make a significant decision by 2027 regarding the use of psilocybin for treating depression in clinical settings. Advocates are particularly focused on its potential benefits for veterans facing treatment-resistant PTSD, a demographic that experiences high suicide rates, as highlighted in the 2025 National Veteran Suicide Prevention Annual Report.
Preliminary findings from a qualitative study involving veterans who participated in a controlled psilocybin retreat suggest improvements in mood and social connections. However, experts like Kevin Yang caution that many clinical trials exclude individuals with complex mental health issues, potentially skewing results. Additionally, the rise in recreational use of psychedelics raises concerns about safety and the potential for misuse.
As the conversation around psychedelics continues to evolve, the implications for public health and mental health treatment are significant. The ongoing research and upcoming FDA decisions will likely shape the future landscape of psychedelic therapy, with a focus on ensuring safety and efficacy for diverse patient populations.
